CHELSEA SENDGRAFF
copywriter & content specialist
PAID ADS
​​​Background Info
Medable's decentralized clinical trial platform allows trials to be run simultaneously in-person and remotely.
Their software brings more ease, equity, and precision to medical research by making it easier for:
• patients to participate in medical research
• pharmaceutical companies and clinical trial sites to efficiently run studies
​
​
​​​
Challenge
Address clinical trial staffs' pain points of exclusively conducting in-person research to entice them to learn more about why decentralized trials will relieve their struggles
​
​
Solution
In addition to empathy, in the various ads, I used:
• To establish Medable as a knowledge resource, I used:
-
industry language (for further explanation see 'details about ad language' below the images to the right)
• To establish trust that they are a reputable company, I used statistics such as:
-
'#1 in Everest PEAK matrix'
-
'#1 DCT platform'
-
'built by clinicians, patients advocates, and tech experts'
​
​
​
Notable Outcome
Before introducing a new updating branding, my copy alone saw a 5x better performance than previously run ads
​
​







​
NOTE: Click on the images to enlarge them for better readability.
​
​
​
​
​
​
Details about ad language
​
Patients wearing thin?
​Many studies get delayed, greatly increasing the cost of running the study, because they do not have enough participants sign up for the trial.
A decentralized trial makes it easier for people to participate because they do not have to take extensive time out of their days—which is an excessive burden to low-income patients as well as those with serious medical conditions—to travel to a physical site to participate.
​
Your patients have been patient long enough.
By running trials more efficiently and not having to wait for patients to physically visit a site, Medable's technology helps speed up the length of a clinical trial.
This means that therapies (medicine or technology) can get approved faster and patients benefit from these therapies faster—in certain cases, saving their lives.
​
1000+ patients a day helps keep the IRB revision away.
When a study fails to enroll enough patients, the study documents, such as the IRB, need to be revised—delaying the study timeline and making the study more costly to complete.
​
We've been green lit.
Before a trial can officially begin, it goes through many stages of approval.
When a study is 'green lit', that means that everything has been thoroughly vetted and approved, and the study can officially begin.
​
​
​